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The role of oxidative DNA damage and GSTM1, GSTT1, and hOGG1 
gene polymorphisms in coronary artery disease risk
Introduction
Coronary artery disease (CAD), which is one of the most 
frequent causes of death, is associated with chronic inflamma-
tion of the arterial intima and is characterized by the formation 
of atherosclerotic plaques (1). Epidemiological studies have 
demonstrated that CAD is a multifactorial disease caused by 
one or more genes in combination with environmental factors, 
including gene–environment interactions (2). Oxidative DNA 
damage has been investigated in CAD cases, and some evi-
dence of increased reactive oxygen species (ROS) formation 
and impaired antioxidant protection during disease progres-
sion has been provided (3–6). Moreover, some genetic variants 
have been associated with the risk of developing CAD (7, 8). 
Therefore, a study of the interactions between the polymor-
phisms of several genes, especially the ones coding phase I 
and phase II detoxification enzymes such as CYPs or glutathi-
one S-transferase (GSTs), and oxidative DNA damage may be 
helpful in understanding the mechanism of this atherosclerotic 
disease. The GST gene family, which encodes phase II metabo-
lizing enzymes, plays an important role in the biotransforma-
tion and detoxification of different xenobiotics and endogenous 
compounds. Since many GST genes are polymorphic, there has 
been considerable interest in determining whether particular 
allelic variants are associated with an altered risk (or outcome) 
of a variety of diseases, including CAD (9, 10).
Two polymorphic genes of this family, GSTM1 and GSTT1, 
present null alleles that consequently do not produce the res-
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pective enzyme when the genotype is homozygous. The poly-
morphisms of these two enzymes are often studied together for 
many diseases. These enzymes convert many electrophilic toxic 
chemicals, which damage macromolecules including DNA, to 
less harmful compounds through glutathione conjugation. Many 
carcinogenic and toxic molecules that produce DNA damage 
can contribute to the development of CAD. The polymorphisms 
of GSTM1 and GSTT1 genes may affect enzymatic activity and 
susceptibility to CAD. On the other hand, the polymorphisms of 
DNA repair genes may also be associated with insufficient DNA 
repair and may influence individual susceptibility to CAD. Base 
excision repair (BER) is a DNA repair pathway that operates on 
small lesions such as oxidized or reduced bases, fragmented 
or non-bulky adducts, or those produced by methylating agents 
(11). hOGG1 is a DNA glycosylase that recognizes and removes 
the altered base (8-OHdG) in the BER pathway. It is encoded by 
the hOGG1 gene localized on chromosome 3p25. Among several 
polymorphisms of the hOGG1 gene, Ser326Cys polymorphism is 
one of the most important, in which C/G polymorphism at posi-
tion 1245 in exon 7 results in an amino acid substitution of serine 
with cysteine in codon 326 (12).
The alkaline comet assay, which detects single-strand breaks 
(SSBs) as well as alkaline-labile sites, is one of the most promis-
ing biomarkers. Recently, it has been modified to analyze oxida-
tive DNA damage using lesion-specific enzymes [(endonuclease 
III (Endo III) and formamidopyrimidine glycosylase (Fpg)] and has 
been accepted as a reliable biomarker for oxidative stress (13).
In the present study, we aimed to investigate the roles of oxi-
dative DNA damage and some polymorphisms in oxidative stress 
(GSTM1 and GSTT1) and DNA repair (hOGG1 Ser326Cys) genes 
in terms of individual susceptibility to CAD. We also investigated 
the interaction between oxidative DNA damage and the poly-
morphisms of these genes in CAD patients.
Methods
Subjects
The study population consisted of 59 patients who had un-
dergone coronary angiography. Of these, 29 patients had an-
giographically documented CAD (24 men, 5 women; mean age, 
61.5±10.3 years); 30 patients with angiographically documented 
normal coronary arteries were considered as the control group 
(24 men, 6 women; mean age, 60.4±11.6 years). Significant CAD 
was defined as a stenosis of ≥50% in any of the main coronary 
arteries, and control subjects were enrolled if they had neither a 
history nor clinical evidence of CAD. The severity of CAD was de-
termined by the number of affected vessels (one-, two-, or three-
vessel disease). The severity of the disease was also evaluated 
by calculating the Gensini score (14, 15).
Details of patients and controls that were recorded at the 
time of sampling included age, gender, smoking status, a family 
history of CAD, a history of hypertension, diabetes, and hyperlipid-
emia, and serum lipid profiles [low-density lipoprotein cholesterol 
(LDL), high-density lipoprotein cholesterol (HDL), total cholester-
ol, and triglyceride levels]. Exclusion criteria were the presence 
of neoplastic disease, acute or chronic inflammatory disease, 
and immunological disease and a history of recent major surgi-
cal procedures. Medications used by patients generally included 
calcium channel blockers, angiotensin-converting enzyme (ACE) 
inhibitors, nitrates, statins, and oral aspirin. None of the patients 
or control subjects were receiving any antioxidant drugs such as 
vitamins. Written informed consent was obtained from all partici-
pants, and the study was approved by the local ethics committee.
Blood sampling
Lymphocytes were obtained from venous blood samples 
supplemented with heparin for the comet assay. Blood for ge-
notyping was collected in tubes coated with EDTA. After col-
lection and during transport, the samples were kept at 4°C and 
protected from light. The comet assay was started no later than 
24 h after sampling. Blood samples for genotyping were stored 
at –80°C until use. Samples from patients and controls were con-
currently handled.
Modified comet assay
From each individual, 2 mL of whole blood was added to 
1% Mg2+-free phosphate-buffered saline (PBS) and underlayed 
with Histopaque 1077 (Sigma, Steinheim, Germany). Cells were 
immediately centrifuged at 200 xg for 3 min at 4°C. Lympho-
cytes were retrieved from just above the boundary between 
PBS and Histopaque, added to PBS, and centrifuged at 200 xg 
for 3 min at 4°C.
The basic alkaline technique was followed, with modifica-
tions for the detection of oxidized bases using bacterial repair 
endonucleases, as previously described (16). Before elec-
trophoresis, the lymphocytes were treated with either buffer 
to examine basal DNA damage or Endo III or Fpg to examine 
pyrimidine or purine base damage, respectively. Freeze-dried 
Endo III (specific for oxidized pyrimidines) and Fpg (recognizes 
altered purines, including 8-oxoGua) were kindly provided by Dr. 
Andrew Collins, University of Oslo, Oslo, Norway. The percent-
age of DNA in the tail (TD%, percentage of tail DNA) was taken 
as a measure of DNA break frequency. TD% was assessed in 50 
cells using the Comet Assay III image analysis system (Percep-
tive Instruments, UK). Analysis was blindly performed by a slide 
reader. Subtracting the TD% without enzyme incubation (i.e., 
strand breaks) from the TD% with enzyme incubation gives the 
net amount of damage, which is represented by pyrimidine (Endo 
III sites) or purine base damage (Fpg sites) (13).
Genotype analysis
Genomic DNA, which was isolated from frozen peripheral 
blood samples using the sodium perchlorate/chloroform extrac-
tion method (17), was used as a template in PCR-based geno-
typing analysis. Genotypes for the selected genes were deter-
mined by the PCR/RFLP method.
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GSTM1 gene
The most important polymorphism encodes a partial gene 
deletion at the GSTM1 locus on chromosome 1p13.3 (GSTM1 null 
genotype), resulting in the complete absence of GSTM1 enzyme 
activity. For detecting this deletion, the PCR primers used were 
Primer 1 (AA1-forward): 5’-CGC CAT CTT GTG CTA CAT TGC CCG-
3’; Primer 2 (AA2-reverse): 5’-ATC TTC TCC TCT TCT GTC TC-3’; 
and Primer 3 (AA3-reverse): 5’-TTC TGG ATT GTA GCA GAT CA-3’ 
(Thermo, Ulm, Germany). PCR was performed in a total volume 
of 10 µL consisting of 100 ng of genomic DNA, 0.25 mM dNTP 
(Fermentas Hanover, MD, USA), 1.5 mM MgCl2, 0.4 µM of each 
primer, and 1 unit of Taq DNA polymerase (Fermentas) in 1x PCR 
buffer. The PCR program consisted of a 2-min initial denaturation 
step at 94°C, followed by 35 cycles of 1-min denaturation at 94°C, 
1 min 30 s of annealing at 53°C, and 2-min elongation at 72°C. The 
final elongation was for 10 min at 72°C. The specific size of the 
GSTM1 gene PCR product (231 bp) and a control band (158 bp) 
was assessed after electrophoresis on a 2% agarose gel.
GSTT1 gene
The GSTT1 gene, located on chromosome 22q11.23, exhibits a 
deletion polymorphism similar to that of the GSTM1 gene. GSTT1 
genotyping was determined by PCR using the forward primer: 5’-
AGG CAG CAG TGG GGG AGG ACC-3’ and reverse primer: 5’-CTC 
ACC GGA TCA TGG CCA GCA-3’. GSTP1 primers (GSTP1-forward: 
5’-ACC CCA GGG CTC TAT GGG AA-3’ and GSTP1-reverse: 5’-TGA 
GGG CAC AAG AAG CCC CT-3’) were also included as controls 
in the PCR mixture to see the independent amplification of each 
sample. PCR was performed in a total volume of 10 µL consisting 
of 100 ng of genomic DNA, 0.2 mM dNTP (Fermentas Hanover, 
MD, USA), 2 mM MgCl2, 0.25 µM of each primer, and 1 unit of Taq 
DNA polymerase (Fermentas) in 1x PCR buffer. The PCR program 
consisted of a 5-min initial denaturation step at 94°C, followed 
by 30 cycles of 1-min denaturation at 94°C, 1-min annealing at 
60°C, and 2-min elongation at 72°C. The final elongation was for 
10 min at 72°C. The specific size of the GSTT1 gene PCR product 
(138 bp) and a control band (158 bp) was assessed after electro-
phoresis on a 2% agarose gel. Null genotypes were scored after 
GSTP1 amplifications were confirmed.
hOGG1 gene
For the genotyping of codon 326 of hOGG1, the following prim-
ers were designed to encompass the Ser326Cys polymorphic site: 
hOGG1-forward 5’: 5’-ACT GTC ACT AGT CTC ACC AG-3’; hOGG1-
reverse 3’: 5’-TGA ATT CGG AAG GTG CTT GGG GAA T-3’ (Thermo, 
Ulm, Germany). PCR was performed in a total volume of 20 µL 
consisting of 100 ng of genomic DNA, 0.25 mM dNTP (Fermen-
tas Hanover, MD, USA), 1.5 mM MgCl2, 0.3 pmol of each primer, 
and 1 unit of Taq DNA polymerase (Fermentas) in 1x PCR buffer. 
The PCR program consisted of a 2-min initial denaturation step at 
94°C, followed by 33 cycles of 15-s denaturation at 94°C, 30-s an-
nealing at 60°C, and 35-s elongation at 72°C. The final elongation 
was for 10 min at 72°C. PCR yielded a 207-bp product. After PCR, 
a 10-µL aliquot of the amplification product was digested (over-
night at 37°C) by 2 units Fnu4HI (NEB, England, UK). The digestion 
products were separated after electrophoresis on a 3% NuSieve 
agarose gel, and the DNA fragments were visualized with 10 mg/
mL ethidium bromide. Consequently, the Ser/Ser, Ser/Cys, and 
Cys/Cys genotypes resulted in 207-bp; 207-, 107-, and 100-bp; and 
107- and 100-bp digestion products, respectively.
Statistical analysis
Data analysis was performed using SPSS for Windows, ver-
sion 11.5. Whether the continuous variables were distributed nor-
mally or not, they were determined using the Shapiro–Wilk test. 
Data were shown as mean±standard deviation or median (IQR) 
for continuous variables, where appropriate. The differences in 
medians between the control and CAD groups were compared 
by the Mann–Whitney U test. Nominal data were evaluated by 
the continuity correction chi-square or Fisher’s exact test, where 
applicable. Univariate logistic regression analyses were applied 
for determining the associations between each continuous vari-
able and the presence of CAD. Odds ratios and 95% confidence 
intervals were calculated. Degrees of association between the 
continuous variables were evaluated by Spearman’s rank correla-
tion test. Whether each genotype (i.e. GSTM1, GSTT1 and hOGG1) 
has a statistically significant effect on the presence of CAD was 
evaluated by multiple logistic regression analyses after adjustment 
for age, gender, the presence of hypertension, and smoking habits. 
Adjusted odds ratios and 95% confidence intervals were also cal-
culated. A p value of <0.05 was considered statistically significant.
Results
The demographic and clinical characteristics of patients 
and controls are presented in Table 1. A statistically significant 
association was found between age and the presence of CAD 
(p=0.02, OR=1.06 95% CI=1.01–1.12). The number of hyperten-
sive subjects in the patient group was significantly higher than 
that in the control group (p=0.015, OR=4.64, 95% CI=1.48–14.54). 
Seven patients had a family history of CAD, whereas none of the 
controls had a family history of CAD (p=0.005). No significant 
differences were observed between the groups with respect to 
gender, smoking habits, and other risk factors.
The distribution and frequency of GSTM1, GSTT1, and hOGG1 
genotypes for patients and controls are given in Table 2. Among the 
control population, the frequency of selected polymorphic vari-
ants were GSTM1 (null), 0.59; GSTT1 (null) 0.21; hOGG1 (Cys/Cys), 
0.07, and these frequencies were not different from those (0.47, 
0.17, and 0.07, respectively) in the studied patient population. The 
results of multiple logistic regression analyses after adjustment 
for age, gender, the presence of hypertension, and smoking habits 
are also given in Table 2. No deviation from the Hardy–Weinberg 
equilibrium was seen for any of the genotypes studied.
Significant differences were observed in basal DNA damage 
in terms of TD% between patients and controls (Table 3). Basal 
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DNA damage levels in patients [9.16 (3.26)] were significantly 
higher than those in controls [7.59 (3.23); p=0.017]. The addition 
of Endo III or Fpg enzymes caused an increase in SSBs in both 
patients and controls, demonstrating the presence of pyrimi-
dine and purine base damage in DNA. However, these increases 
were not statistically different between the groups (p>0.05). 
The influences of GSTM1, GSTT1, and hOGG1 genotypes on 
oxidative DNA damage parameters are presented in Table 4. No 
significant differences were observed between individuals car-
rying the GSTM1, GSTT1, and hOGG1 variant or the wild genotype 
in terms of oxidative DNA damage parameters in both controls 
and patients. However, basal DNA damage levels were statisti-
cally different in patients as compared with in controls carrying 
the same genotypes. Patients carrying the GSTT1 active genotype 
or Ser/Cys + Cys/Cys variants of the hOGG1 showed higher levels 
of basal DNA damage compared with controls carrying the same 
genotypes (p=0.014 and 0.022 respectively).
The correlations between the Gensini score as a marker 
of CAD severity and oxidative DNA damage parameters are 
presented in Table 5. There were significant correlations 
between the Gensini score and basal DNA damage (r=0.352, 
p=0.006) and pyrimidine base damage r=0.318, p=0.014), 
whereas no significant correlation was observed for purine 
base damage (p>0.05).
Table 1. Demographic and clinical characteristics of patients and controls
  CAD patients (n=29) Controls (n=30) OR (95%CI) P
Age, years±SD 61.5±10.3 54.4±11.6 1.06 (1.01–1.12) 0.020†
Gender, Men/Women, n (%) 24 (82.8)/5 (17.2) 24 (80)/6 (20) 0.83 (0.22–3.10) 1.000‡
Hypertension, n (%) 17 (60.7) 7 (25) 4.64 (1.48–4.54) 0.015‡
Diabetes mellitus, n (%) 11 (39.3) 11 (40.7) 0.94 (0.32–2.77) 1.000‡
Hyperlipidemia, n (%) 9 (32.1) 7 (25.9) 1.35 (0.42–4.36) 0.833‡
Smoking, n (%) 16 (55.2) 11 (40.7) 1.79 (0.62–5.17) 0.417‡
Family history, n (%) 7 (24.1) 0 (0) NC 0.005¶
Total cholesterol, mg/dL 187.7±36.1 188.3±62.1 1.00 (0.99–1.01) 0.965†
LDL-cholesterol, mg/dL 101.7±21.3 102.8±44.5 0.99 (0.98–1.01) 0.918†
HDL- cholesterol, mg/dL 45.3±10.4 47.3±19.3 0.99 (0.95–1.03) 0.649†
Triglyceride, mg/dL 265.2±344.4 164.4±84.5 1.00 (0.99–1.01) 0.230†
Gensini score 54.1±36.8 7.4±29.9 1.06 (1.03–1.10) <0.001†
‡Continuity correction chi-square test; ¶Fisher's exact test; †Univariate logistic regression analyses; CAD - coronary artery disease; HDL - high–density lipoprotein cholesterol; 
LDL - low-density lipoprotein cholesterol; NC - not calculated
Table 2. Distribution n (%) of GSTM1, GSTT1 and hOGG1 genotypes in patients and controls
  CAD patients Controls OR (95% CI) P Adjusted* OR (95% CI) P
GSTM1
 Active 12 (41.4) 16 (53.3)    
 Null 17 (58.6) 14 (46.7) 1.619 (0.578–4.534) 0.510† 0.325 (0.082–1.293) 0.111
GSTT1
 Active 23 (79.3) 25 (83.3)    
 Null 6 (20.7) 5 (16.7) 1.304 (0.350–4.858) 0.950† 1.005 (0.200–5.041) 0.995
hOGG1
 Ser/Ser 15 (51.7) 17(56.7)    
 Ser/Cys 12 (41.4) 11 (36.7) 1.236 (0.423–3.615) 0.909† 1.230 (0.327–4.631) 0.759
 Cys/Cys 2 (6.9) 2 (6.7) 1.133 (0.142–9.065) 1.000‡ 0.510 (0.038–6.861) 0.612
*Adjusted for age, gender, presence of hypertension and smoking habits; †Continuity correction chi-square test; ‡Fisher's exact test; CAD - coronary artery disease
Table 3. Oxidative DNA damage in patients and controls. Values are 
median (IQR)
  CAD patients Controls P
Basal DNA damage 9.16 (3.26) 7.59 (3.23) 0.017
Pyrimidine base damage 
(Endo III sites) 15.04 (12.07) 11.02 (6.98) 0.08
PBD (Fpg sites) 12.38 (6.98) 12.24 (4.80) 0.55
Mann-Whitney U test. CAD - coronary artery disease; PBD - purine base damage
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Discussion
In the present study, we investigated two different types 
of biomarkers in CAD patients. We assessed a biomarker of 
effect (DNA damage) and a biomarker of susceptibility (gene 
polymorphism) for CAD risk. Our results significantly high-
lighted increased basal DNA damage levels in CAD patients 
with respect to controls. However, neither pyrimidine nor pu-
rine base damage levels, which reflect oxidative DNA dam-
age, were significantly different between the groups. On the 
other hand, basal DNA and pyrimidine base damage levels 
were significantly correlated with disease severity based on 
Gensini scoring. Although there were some significant differ-
ences in terms of basal DNA damage between the patients 
and controls carrying the same alleles, genotype analysis 
did not reveal a clear association between any of the studied 
SNPs (GSTM1, GSTT1, and hOGG1) and CAD. Although the re-
sults of our study pointed out the effects of age, hypertension, 
and family history as possible risk factors for CAD, none of 
these factors affect the frequency of the polymorphisms after 
adjusting the results for age, gender, the presence of hyper-
tension, and smoking habits.
The association between DNA damage and CAD was in-
vestigated in several studies, and there is increasing evidence 
that DNA damage plays an important role in atherogenesis. 
Botto et al. (5) investigated micronucleus (MN) frequency in 
CAD patients and found that MN levels were higher in these 
patients than in controls. They also observed a relationship 
between increased MN frequencies and disease severity. In a 
follow-up study, major adverse cardiovascular events (MAC-
Es) such as heart failure, stroke, or cardiovascular death were 
reported in CAD patients for a period of 51 months, and MN 
levels were found to be significantly higher in patients who 
had MACEs than in those who did not (18). Many factors can 
cause DNA damage, including mainly oxidative stress. Oxida-
tive stress to lipids and DNA caused by free radicals is known 
to be one of the several fundamental mechanisms that are 
responsible for developing atherosclerosis and cancer (19). 
Some possible atherogenic mechanisms, such as increasing 
ROS production, the potentiation of LDL oxidation, and the 
diminished release of nitric oxide, were suggested in vari-
ous studies (20, 21). Oxidative stress-related studies in CAD 
patients have usually been performed by measuring the lipid 
peroxidation or antioxidant capacity in plasma (4, 22). Howev-
er, the number of studies on oxidative DNA damage in CAD pa-
tients is limited, and the information in the literature regarding 
the role of DNA damage in the etiology of CAD is inadequate. 
In the present study, we observed significantly increased lev-
els of basal DNA damage but not oxidative DNA damage in the 
lymphocytes of CAD patients. This finding indicates possible 
damage to the DNA of these patients; however, this damage, 
as detected by the modified comet assay, was not a result 
of oxidized DNA bases. Moreover, basal DNA damage levels 
in patients were positively correlated with disease severity. 
Similar studies using the alkaline comet assay have been pre-
viously conducted for investigating oxidative DNA damage in 
CAD patients. Botto et al. (6) demonstrated that increased lev-
els of SSBs and oxidized DNA bases correlated with the sever-
ity of CAD in patients. Demirbağ et al. (4, 23) investigated DNA 
damage using the standard alkaline comet assay (not modi-
Table 4. Influences of GSTM1, GSTT1 and hOGG1 genotypes on 
oxidative DNA damage parameters in patients and controls. Values 
are mean±SD
  Genotype CAD patients Controls
  GSTM1 active 8.96±2.13 7.58±2.00
  GSTM1 null 9.80±3.16 8.59±3.30
  GSTT1 active 9.32±2.74* 7.74±2.74
Basal DNA GSTT1 null 9.96±3.08 9.62±1.94
damage Ser/Ser 8.33±2.76 7.51±1.72
  Ser/Cys 10.55±2.46 7.56±2.01
  Cys/Cys 11.30±1.26 15.40±2.61
  Ser/Cys+Cys/Cys 10.66±2.30** 8.76±3.55
  GSTM1 active 16.50±9.69 12.19±5.94
  GSTM1 null 18.32±7.52 17.39±11.47
Pyrimidine GSTT1 active 16.20±8.32 13.69±8.80
base GSTT1 null 22.83±6.78 19.25±10.63
damage Ser/Ser 14.95±6.40 14.04±7.28
(Endo III sites) Ser/Cys 18.48±8.83 15.77±12.48
  Cys/Cys 31.70±4.17 13.16±3.13
  Ser/Cys+Cys/Cys 20.37±9.51 15.37±11.47
  GSTM1 active 10.91±4.97 11.03±2.81
  GSTM1 null 16.50±5.62 17.00±7.81
Purine GSTT1 active 12.61±5.29 12.74±4.20
base GSTT1 null 20.23±4.56 19.19±12.06
damage Ser/Ser 12.62±5.94 14.53±7.20
(Fpg sites) Ser/Cys 15.09±5.75 13.03±5.68
  Cys/Cys 20.52±3.40 12.13±2.16
  Ser/Cys+Cys/Cys 15.86±5.73 12.89±5.23
*P=0.014 (vs controls); **P=0.022 (vs. controls); Mann-Whitney U test. CAD - coronary 
artery disease
Table 5. Correlation between oxidative DNA damage parameters and 
Gensini score 
  Correlation coefficient (r) Significance (P)
Basal DNA damage 0.352 0.006
Pyrimidine base damage 0.318 0.014 
(Endo III sites)
PBD, (Fpg sites) 0.110 0.408
Spearman’s correlation test. PBD - purine base damage
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fied with repair enzymes) in CAD patients and reported higher 
SSBs and lower plasma total antioxidant capacity levels in 
patients with acute coronary syndrome than those in patients 
with stable angina and healthy subjects. In another study, 
contrary to our findings, significantly increased levels of oxi-
dized pyrimidine and purine bases were found; however, no 
significant difference was reported in terms of SSBs between 
CAD patients and controls (24). Recently, Rajesh et al. (3) as-
sessed DNA damage using the standard comet assay in a 
rather large population of CAD patients and reported signifi-
cantly higher levels of DNA damage as well as malondialde-
hyde (MDA) and nitrite/nitrate levels in patients than those in 
controls.
In the present study, the roles of GSTM1, GSTT1, and 
hOGG1 gene polymorphisms and their relationship with oxi-
dative DNA damage were also investigated in CAD patients. 
The GSTM1 null genotype is very common among Caucasians 
and is found in approximately 50% of the population (25). A 
homozygous deletion of the GSTT1 gene (null genotype) is 
found in 10%–20% of Caucasians, making them unable to per-
form GSTT1-mediated detoxification reactions (26). Genes 
coding for DNA repair molecules, such as hOGG1, have been 
proposed as candidate susceptibility genes because of the 
importance of maintaining genomic integrity. (11). Our results 
regarding the frequencies of studied gene polymorphisms 
are consistent with those of previous Turkish studies (27, 28). 
However, our results did not show any statistical difference 
between CAD patients and controls in terms of GSTM1, GSTT1, 
and hOGG1 variant allele frequency. There are some previous 
studies investigating the effect of these polymorphisms on 
the risk of developing CAD, and the findings are contradic-
tory. In a recent study, similar to our findings, the frequency of 
the GSTM1 and GSTT1 null alleles did not differ among CAD 
patients and controls; however, a combined effect of CYP1A1 
and GSTT1 variant genotypes was reported for the risk of de-
veloping CAD (7). Similarly, Bazo et al. (29) did not detect any 
association between GSTM1 and GSTT1 gene polymorphisms 
and coronary atherosclerosis in a Brazilian population. On the 
other hand, Girisha et al. (30) reported a decreased frequency 
of the GSTT1 null genotype and no significant association with 
GSTM1 genotypes in CAD patients compared with in controls. 
An association between GST polymorphisms and CAD risk is 
demonstrated mostly in studies investigating the interaction 
of these polymorphisms with cigarette smoking. In three dif-
ferent studies, a strengthened effect of GST-null genotypes on 
smoking-induced CAD risk was reported, although GST null 
genotypes did not differ between patients and controls (10, 
31, 32). Similar results were obtained in a large cohort study 
pointing out a positive interaction with the GSTT1 null geno-
type (8).
hOGG1 is one of the polymorphic repair genes in the BER 
pathway, which has a critical role in removing damaged DNA 
bases. It catalyzes the cleavage of the glycosylic bond be-
tween the modified base and the sugar moiety; as a result, an 
abasic apurinic or apyrimidinic (AP) site occurs in the DNA. 
Studies on the role of hOGG1 gene polymorphism in CAD 
risk are limited. Two recent studies on a Taiwanese popula-
tion demonstrated contradictory results. Wang et al. (33) re-
ported an association between hOGG1 polymorphism and an 
increased risk of CAD, whereas Shyu et al. (34) found no as-
sociation. In a cohort study, 98 subjects suffering from severe 
atherosclerotic lesions were followed up for 14 years, and an 
adverse effect on survival was detected in subjects having 
the double GSTM1 and GSTT1 deletion, although the frequen-
cies of both null alleles were not different from the general 
population. In the same study, the survival rate was not in-
fluenced by hOGG1 polymorphism (35). Gökkuşu et al. (36) 
investigated the role of different DNA repair enzyme polymor-
phisms in progressing CAD, and they reported that XRCC3 and 
hOGG1 genetic variants may be risk factors that may lead to 
the development of CAD. Another study on a Chinese popula-
tion revealed similar results in coronary ectasia patients, with 
a significant association of hOGG1 Ser326Cys polymorphism. 
The study also reported higher 8-OHdG levels in subjects car-
rying the hOGG1 variant allele (37).
During the past few years, a large number of studies have 
focused on individual susceptibility for predicting the risk of 
developing some common diseases such as cancer and ath-
erosclerosis. A variety of factors can contribute to variations 
in the individual response to environmental mutagenic agents, 
thus causing some individuals to be susceptible to these dis-
ease and others to be resistant. Moreover, combinations of 
biomarkers are valuable in assessing the individual risk of 
diseases (38, 39).
Study limitations
The small sample size limited us from analyzing more fac-
tors involving the risk of CAD, such as smoking. Therefore, 
these preliminary findings need to be validated in larger popu-
lations.
Conclusion
In this study, we demonstrated the role of DNA damage 
in CAD; however, no significant differences were observed 
in terms of oxidized DNA bases between patients and con-
trols. Therefore, we can conclude that the DNA damage we 
observed does not originate from ROS. In the present study, 
the studied genotypes (GSTM1, GSTT1, and hOGG1) showed 
similar frequencies between groups. Although there were 
some significant differences in terms of basal DNA damage 
between the patients and controls carrying the same alleles, 
genotype analysis did not reveal a clear association between 
any of the studied SNPs and CAD.
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